Big data and stratified medicine: what does it mean for children?

Ding, Wen Y, Beresford, Michael W ORCID: 0000-0002-5400-9911, Saleem, Moin A and Ramanan, Athimalaipet V (2019) Big data and stratified medicine: what does it mean for children? ARCHIVES OF DISEASE IN CHILDHOOD, 104 (4). pp. 389-394.

Text Big data and Stratified medicine — What does it mean for children - StratMed 4th draft 20180806 WYD v1.4 for resubmission clean version.docx - Author Accepted Manuscript Download (85kB)

Abstract

Stratified medicine in paediatrics is increasingly becoming a reality, as our understanding of disease pathogenesis improves and novel treatment targets emerge. We have already seen some success in paediatrics in targeted therapies such as cystic fibrosis for specific cystic fibrosis transmembrane conductance regulator variants. With the increased speed and decreased cost of processing and analysing data from rare disease registries, we are increasingly able to use a systems biology approach (including '-omics') to screen across populations for molecules and genes of interest. Improving our understanding of the molecular mechanisms underlying disease, and how to classify patients according to these will lead the way for targeted therapies for individual patients. This review article will summarise how 'big data' and the 'omics' are being used and developed, and taking examples from paediatric renal medicine and rheumatology, demonstrate progress being made towards stratified medicine for children.

Item Type:	Article
Uncontrolled Keywords:	Humans, Rare Diseases, Registries, Proteomics, Computational Biology, Systems Biology, Genomics, Pediatrics, Forecasting, Child, Metabolomics, Transcriptome, Big Data
Depositing User:	Symplectic Admin
Date Deposited:	11 Sep 2018 14:52
Last Modified:	19 Jan 2023 01:18
DOI:	10.1136/archdischild-2018-315125
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3026111